Seim Bjørn Edvard, Holt Margrethe Flesvig, Ratajska Aleksandra, Michelsen Annika, Ringseth Monica Myklebust, Halvorsen Bente Evy, Skjelland Mona, Kvitting John-Peder Escobar, Lundblad Runar, Krohg-Sørensen Kirsten, Osnes Liv T N, Aukrust Pål, Paus Benedicte, Ueland Thor
Department of Cardiothoracic Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Front Cardiovasc Med. 2022 Dec 20;9:1073069. doi: 10.3389/fcvm.2022.1073069. eCollection 2022.
In approximately 20% of patients with thoracic aortic aneurysms or dissections a heritable thoracic aortic disease (HTAD) is suspected. Several monogenic connective tissue diseases imply high risk of aortic disease, including both non-syndromic and syndromic forms. There are some studies assessing inflammation and extracellular matrix remodeling in patients with non-hereditary aortic disease, but such studies in patients with hereditary diseases are scarce.
To quantify markers of extracellular matrix (ECM) and inflammation in patients with vascular connective tissue diseases versus healthy controls.
Patients with Loeys-Dietz syndrome (LDS, = 12), Marfan syndrome (MFS, = 11), and familial thoracic aortic aneurysm 6 (FTAA6, = 9), i.e., actin alpha 2 (ACTA2) pathogenic variants, were recruited. Exome or genome sequencing was performed for genetic diagnosis. Several markers of inflammation and ECM remodeling were measured in plasma by enzyme immunoassays. Flow cytometry of T-cell subpopulations was performed on a subgroup of patients. For comparison, blood samples were drawn from 14 healthy controls.
(i) All groups of HTAD patients had increased levels matrix metalloproteinase-9 (MMP-9) as compared with healthy controls, also in adjusted analyses, reflecting altered ECM remodeling. (ii) LDS patients had increased levels of pentraxin 3 (PTX3), reflecting systemic inflammation. (iii) LDS patients have increased levels of soluble CD25, a marker of T-cell activation.
Our data suggest that upregulated MMP-9, a matrix degrading enzyme, is a common feature of several subgroups of HTAD. In addition, LDS patients have increased levels of PTX3 reflecting systemic and in particular vascular inflammation.
在大约20%的胸主动脉瘤或夹层患者中,怀疑患有遗传性胸主动脉疾病(HTAD)。几种单基因结缔组织疾病意味着主动脉疾病的高风险,包括非综合征型和综合征型。有一些研究评估了非遗传性主动脉疾病患者的炎症和细胞外基质重塑,但遗传性疾病患者的此类研究很少。
量化血管结缔组织疾病患者与健康对照者的细胞外基质(ECM)和炎症标志物。
招募了患有洛伊茨-迪茨综合征(LDS,n = 12)、马凡综合征(MFS,n = 11)和家族性胸主动脉瘤6型(FTAA6,n = 9),即肌动蛋白α2(ACTA2)致病变异的患者。进行外显子组或基因组测序以进行基因诊断。通过酶免疫测定法测量血浆中的几种炎症和ECM重塑标志物。对一组患者进行了T细胞亚群的流式细胞术检测。为了进行比较,从14名健康对照者中采集了血样。
(i)与健康对照者相比,所有HTAD患者组的基质金属蛋白酶-9(MMP-9)水平均升高,在调整分析中也是如此,这反映了ECM重塑的改变。(ii)LDS患者的五聚体3(PTX3)水平升高,反映全身炎症。(iii)LDS患者的可溶性CD25水平升高,CD25是T细胞活化的标志物。
我们的数据表明,上调的MMP-9(一种基质降解酶)是HTAD几个亚组的共同特征。此外,LDS患者的PTX3水平升高,反映全身尤其是血管炎症。